J
Jaime Ferrer-Lozano
Researcher at University of Valencia
Publications - 14
Citations - 1799
Jaime Ferrer-Lozano is an academic researcher from University of Valencia. The author has contributed to research in topics: Breast cancer & Metastatic breast cancer. The author has an hindex of 9, co-authored 12 publications receiving 1573 citations.
Papers
More filters
Journal ArticleDOI
A Genomic Predictor of Response and Survival Following Taxane-Anthracycline Chemotherapy for Invasive Breast Cancer
Christos Hatzis,Lajos Pusztai,Vicente Valero,Daniel J. Booser,Laura J. Esserman,Ana Lluch,Tatiana Vidaurre,Frankie A. Holmes,Eduardo A. Souchon,Hongkun Wang,Miguel Martin,Jose M. Cotrina,Henry L. Gomez,Rebekah Hubbard,J. Ignacio Chacón,Jaime Ferrer-Lozano,Richard Dyer,Meredith Buxton,Yun Gong,Yun Wu,Nuhad K. Ibrahim,Eleni Andreopoulou,Naoto T. Ueno,Kelly K. Hunt,Wei Yang,Arlene Nazario,Angela DeMichele,Joyce O'Shaughnessy,Gabriel N. Hortobagyi,W. Fraser Symmans +29 more
TL;DR: A genomic predictor combining ER status, predicted Chemoresistance, predicted chemosensitivity, and predicted endocrine sensitivity identified patients with high probability of survival following taxane and anthracycline chemotherapy.
Journal ArticleDOI
Emergence of constitutively active estrogen receptor-α mutations in pretreated advanced estrogen receptor positive breast cancer
Rinath Jeselsohn,Roman Yelensky,Gilles Buchwalter,Gilles Buchwalter,Garrett M. Frampton,Funda Meric-Bernstam,Ana M. Gonzalez-Angulo,Jaime Ferrer-Lozano,Jose Alejandro Perez-Fidalgo,Massimo Cristofanilli,Henry L. Gomez,Carlos L. Arteaga,Jennifer M. Giltnane,Justin M. Balko,Maureen T. Cronin,Mirna Jarosz,James Sun,Matthew J. Hawryluk,Doron Lipson,Geoff Otto,Jeffrey S. Ross,Addie Dvir,Lior Soussan-Gutman,Ido Wolf,Tamar Rubinek,Lauren Gilmore,Stuart J. Schnitt,Steven E. Come,Lajos Pusztai,Philip J. Stephens,Myles Brown,Myles Brown,Vincent A. Miller +32 more
TL;DR: Functional studies in cell line models demonstrate that functional ESR1 mutations render estrogen receptor constitutive activity and confer partial resistance to currently available endocrine treatments during the progression of ER+ breast cancer.
Journal ArticleDOI
PI3K pathway mutations and PTEN levels in primary and metastatic breast cancer
Ana M. Gonzalez-Angulo,Jaime Ferrer-Lozano,Katherine Stemke-Hale,Aysegul A Sahin,Shuying Liu,Juan Antonio Barrera,Octavio Burgues,Ana Lluch,Huiqin Chen,Gabriel N. Hortobagyi,Gordon B. Mills,Funda Meric-Bernstam +11 more
TL;DR: There is a high level of discordance in PTEN level, PIK3CA mutations, and receptor status between primary tumors and metastases that may influence patient selection and response to PI3K-targeted therapies.
Journal ArticleDOI
Nuclear PARP-1 protein overexpression is associated with poor overall survival in early breast cancer
Federico Rojo,Jetzabel Garcia-Parra,Sandra Zazo,Ignasi Tusquets,Jaime Ferrer-Lozano,Silvia Menendez,Pilar Eroles,Cristina Chamizo,Sonia Servitja,N. Ramírez-Merino,Francisco Lobo,Beatriz Bellosillo,J.M. Corominas,José Yélamos,Sergi Serrano,Ana Lluch,Ana Rovira,Joan Albanell +17 more
TL;DR: Nuclear PARP-1 is overexpressed during the malignant transformation of the breast, particularly in triple-negative tumors, and independently predicts poor prognosis in operable invasive breast cancer.
Journal ArticleDOI
High ERK Protein Expression Levels Correlate with Shorter Survival in Triple-Negative Breast Cancer Patients
Chandra Bartholomeusz,Ana M. Gonzalez-Angulo,Ping Liu,Naoki Hayashi,Ana Lluch,Jaime Ferrer-Lozano,Gabriel N. Hortobagyi +6 more
TL;DR: In conclusion, ERK-2 and pMAPK are valuable prognostic markers in TNBC and further studies are justified to elucidate ERK's role in T NBC tumorigenicity and metastasis.